Vericel Watchlist

tz-plus logo Pivotal-Point Tracking Vericel (VCEL): Biotech specialist for cell therapies impresses with 26% revenue growth in Q3

W. Zussner
Reading Time: 1 minute

Vericel develops cell-based specialty therapies for the repair of knee cartilage damage (MACI) and for the treatment of severe burns (Epicel, NexoBrid). On November 5, 2026, the shares jumped nearly 14% after the company significantly exceeded expectations in the third quarter. Revenue climbed 26% year-over-year to $85.4 million, while net profit surged 179% to $14.2 million ($0.27 per share). Additionally, management raised its annual targets for the third consecutive time, now expecting revenues between $344 and $346 million instead of the previous...

Read this article now with a free account.

Your benefits:

  • Every month, you can read 5 articles from the premium section for free.
  • Monthly 2 trial issues of the Trader newspaper for free.
  • Create a personal watchlist with an overview of news about your stock.
Trader Times
Free account
Here we go!
Image 1Image 2Image 3

Already registered? Log In